Skip to Content Facebook Feature Image

Field of Dreams Just Got A Whole Lot Louder: Nickelback Set to Headline “Velocity” on Sunday, August 31st

News

Field of Dreams Just Got A Whole Lot Louder: Nickelback Set to Headline “Velocity” on Sunday, August 31st
News

News

Field of Dreams Just Got A Whole Lot Louder: Nickelback Set to Headline “Velocity” on Sunday, August 31st

2025-03-18 23:01 Last Updated At:23:13

NEW YORK--(BUSINESS WIRE)--Mar 18, 2025--

Field of Dreams is about to get a whole lot louder! U.S. Concert Agency (USCA) and StubHub have announced the addition of a second day to the highly anticipated concert event at the legendary Field of Dreams in Dyersville, Iowa. Nickelback will headline Day 2 on Sunday, August 31st, 2025, bringing their high-energy rock performance to this iconic location. For USCA, this is the kick off of Velocity, a multi-city branded festival that in addition to Nickelback will include Brantley Gilbert and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318620924/en/

Tim McGraw is set to headline Day 1 on Saturday, August 30th, 2025, kicking off an unforgettable weekend of live music.

Nickelback, one of the best-selling rock bands of all time, has sold over 50 million albums worldwide. With massive hits like “How You Remind Me,” “Rockstar,” and “Photograph,” the band has earned multiple Grammy nominations and several American Music Awards and Billboard Music Awards, making them a staple in the rock genre. Their performance at the Field of Dreams will bring an electrifying atmosphere to this historic event.

Tickets for the newly added Nickelback date, with pre-sale on March 19 and general sale on March 21, will be listed on StubHub, the world’s leading marketplace to buy and sell tickets to live events. As the Official Ticket Partner, StubHub will handle all ticket distribution, continuing the successful partnership with USCA, as seen with the first date with Tim McGraw. Fans will have access to a wide range of ticket options and flexibility.

“Adding a second day to this event is going to make it even more epic! With Nickelback hitting the stage at the iconic Field of Dreams, we're kicking off something special with Velocity, our new multi-city music festival launching in 2026. It's all about bringing incredible performances to legendary locations and creating unforgettable experiences for fans. We’re beyond excited for what’s to come!” shared Nick Abate, Founder and CEO of U.S. Concert Agency (USCA).

This two-day celebration will take place on the 193-acre farm made famous by the 1989 film Field of Dreams. Fans will have the rare opportunity to experience live music in one of America’s most iconic locations, combining the magic of the movie with the excitement of top-tier performances.

“We are dedicated to connecting fans to unforgettable experiences and providing unparalleled access on StubHub,” said Adam Budelli, Head of North America Partnerships for StubHub. “By extending our partnership with USCA, we’re powering ticket distribution for this unique Nickelback event – a great example of how we deliver seamless access for fans, while supporting innovative partners and expanding their reach across our global platform.”

The event will honor the history of the Field of Dreams and the spirit of baseball, offering fans an incredible weekend full of music, history, and fun. Stay tuned for more exciting announcements as the event draws closer.

On-Sale Dates – On StubHub:

Ticket Options*:

**Limited supply; max of 6 tickets per order

*Taxes and fees apply.

For more information about tickets, visit www.USCA.live.

This distribution model with USCA underscores a growing focus for StubHub to empower partners’ ability to directly distribute inventory on its platform to over 100 million fans across over 200 countries and territories, supporting partners’ ability to distribute to a wider audience over multiple channels, increase marketing opportunities and support their business goals, all while giving fans access to an even wider selection of tickets.

About U.S. Concert Agency (USCA)

U.S. Concert Agency is a leading promoter and event organizer, known for producing some of the most memorable live events across the country. With a commitment to delivering exceptional experiences for fans, USCA brings unique concerts and events to iconic locations.

About Nickelback

2023 Canadian Music Hall of Fame inductees and Diamond-certified rock legends Nickelback were named Billboard’s “Most Successful Rock Band of the Decade” in 2009. Globally celebrated for career-defining and award-winning hits like “How You Remind Me,” “Photograph,” “Far Away,” “Rockstar,” and more, the four-piece – Chad Kroeger, Ryan Peake, Mike Kroeger, and Daniel Adair – remains one of the most commercially successful and influential acts of the past two decades.

With worldwide sales surpassing 50 million units, Nickelback ranks among the top-selling artists of all time and was the second best-selling foreign act in the U.S. during the 2000s, behind only The Beatles. Their inescapable smash “How You Remind Me” was named Billboard’s Top Rock Song of the Decade and was the most-played song on U.S. radio (all formats) in the 2000s, with over 1.2 million spins, according to Nielsen SoundScan. The track has since cemented its place in streaming history, surpassing one billion streams on Spotify and earning Nickelback a coveted spot in the Spotify Billions Club.

Among their many accolades, Nickelback has been recognized as Billboard’s Top Rock Group of the Decade, earned nine Grammy Award nominations, and won three American Music Awards, a World Music Award, a People’s Choice Award, twelve JUNO Awards, and seven MuchMusic Video Awards. They have been inducted into Canada’s Walk of Fame (2007) and the Canadian Music Hall of Fame (2023).

With 23+ chart-topping singles and a devoted global fanbase, Nickelback continues to dominate the live music scene. Their Get Rollin’ Tour spanned over 72 shows across the globe over two years, playing to more than a million fans worldwide. In addition to their touring success, Nickelback’s story took center stage in 2023 with the release of their critically acclaimed documentary, Hate to Love: Nickelback – now available on Netflix.

About StubHub

StubHub is the world’s leading marketplace to buy and sell tickets to any live event, anywhere. Through StubHub in North America and viagogo, our international platform, we service customers in 200 countries and territories in 33 languages and 48 available currencies. With more than 100 million tickets available to events around the world annually – from sports to music, comedy to dance, festivals to theater – StubHub offers the safest, most convenient way to buy or sell tickets to the most memorable live experiences, with every order backed by our FanProtect Guarantee and global and 24/7 customer service support.

Nickelback

Nickelback

TOKYO--(BUSINESS WIRE)--Mar 19, 2025--

PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology (*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration (*2) and joint research between the two companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318287676/en/

The new production technology enables real-time monitoring of the quality of 3D cell products, which are living cells in three-dimensional structures. This type of monitoring, which has been historically challenging for researchers, in turn supports more stable manufacturing of quality cell products. In this collaboration, Cyfuse used its proprietary Bio 3D Printing technology to manufacture 3D cell constructs and PHC used in-line monitoring technology in its LiCellGrow TM(*3) cell expansion system under development to track metabolic activity in the cell constructs. By combining these technologies, the companies successfully improved the quality and stability of 3D cell products during cultivation.

To build on this development, PHC and Cyfuse aim to develop a next-generation type of cell expansion system called a circulation cell culture system that incorporates the new production technology. This new device will seek to identify critical process parameters in the 3D cell product manufacturing process, monitor cell conditions in real time during production, and optimize the manufacturing process based on the state of the cells. The companies hope to contribute to improving the quality and stability of 3D cell products like those Cyfuse develops.

The details of this development will be presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, scheduled to be held at Pacifico Yokohama in Yokohama, Japan from March 20 to March 22, 2025. The companies will showcase their research findings through poster presentations, focusing on the ongoing development of the circulation cell culture system, as well as the quality evaluation of Cyfuse's 3D cell products cultured using this system.

PHC and Cyfuse will continue to advance their joint research efforts to accelerate the practical application of various production technologies. The companies also aim to expand the value chain within the growing field of regenerative and cell therapy. They will seek to promote research and development, technological innovation, and the creation of new products, including Cyfuse’s regenerative medicine products. Furthermore, by strengthening corporate collaboration including strategic partnerships, PHC and Cyfuse are committed to driving growth and advancement in this field through this partnership.

*1 By utilizing PHC's In-Line Monitoring technology, glucose and lactate concentrations in the culture medium can be measured in real time, allowing for automatic medium replacement based on their concentrations to optimize the culture environment. This technology enables precise control of glucose concentration, one of the critical parameters in the culture process of three-dimensional cellular structures, such as Cyfuse’s 3D cell products, to maintain it at the desired level.
*2 For more details, please refer to the press release dated August 2, 2023, titled “PHC Corporation and Cyfuse Biomedical K.K. Enter into Strategic Collaboration Agreement in the Field of Regenerative and Cell Therapy.”
www.phchd.com/jp/phc/news/2023/0802 (Japanese Only)
www.cyfusebio.com/archives/1216 (Japanese Only)
*3 This product, a cell expansion system for research purposes, is currently under development toward commercialization, including potential implementation for medical applications. A prototype of the device was exhibited at "Regenerative Medicine JAPAN 2024" (held in October 2024).
https://www.phchd.com/jp/phc/news/2024/1001 (Japanese only)

About the Biomedical Division of PHC Corporation

Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO 2 incubators and ultra-low temperature freezers.
www.phchd.com/global/phc

About PHC Holdings Corporation (PHC Group)

PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates three-dimensional tissues solely from cells without artificial scaffolds, the company develops innovative regenerative medicine products and sells Bio 3D printers, Regenova® and S-PIKE®.
For more information, please visit "CYCHANNEL" at www.cyfusebio.com/cychannel.

(Left) PHC: Cell Expansion System LiCellGrow, (Right) Cyfuse: Bio 3D Printer

(Left) PHC: Cell Expansion System LiCellGrow, (Right) Cyfuse: Bio 3D Printer

Recommended Articles
Hot · Posts